-
Safety Board Says Phase 2 Temelimab Trial for MS Should Move Forward
A safety board had recommended that a Phase 2a trial evaluating temelimab for relapsing MS should continue as planned, without modifications. Click here to read the full story.
Did you enjoy this article?
Sorry, there were no replies found.
Log in to reply.